Related Experiment Video
Updated: Jun 21, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients
Alberto Alvarez-Larrán1, Beatriz Bellosillo, Luz Martínez-Avilés
1Haematology Department, Hospital del Mar, IMIM, Barcelona, Spain. 95967@imas.imim.es
Abstract:
Postpolycythaemic myelofibrosis (PPMF) is a known complication of polycythaemia vera (PV) but information regarding its incidence and predisposing factors is not well defined. In 116 subjects consecutively diagnosed with PV in a single institution (median age 62 years, range: 20-88), the probability of PPMF was analysed by the Kaplan-Meier method, followed by the log-rank test. With a mean follow-up of 8 years (95% confidence interval: 6.6-9), 17 patients had evolved into PPMF (15%). The probability of evolution to PPMF was 16% at 10 years and 34% at 15 years. Age, gender, spleen size, leucocytosis, thrombocytosis or cytoreductive treatment were not associated with an increased risk of PPMF. The actuarial probability of PPMF at 15 years was higher in those patients presenting at diagnosis with endogenous megakaryocytic colony formation (59% when present versus 10% when absent, P = 0.03), an elevated serum lactate dehydrogenase (LDH) level (69% vs. 23% in patients with normal LDH, P = 0.04), and in those who were heterozygous for the JAK2 V617F mutation (55% vs. 17% in heterozygotes, P = 0.04). In conclusion, PPMF is a frequent complication in PV patients at 15 years with the risk being higher in patients with increased LDH, endogenous megakaryocytic colony formation or a high JAK2 V617F allele burden.
Insights
Postpolycythaemic myelofibrosis (PPMF) frequently complicates polycythaemia vera (PV), affecting 15% of patients. Higher risk for PPMF is linked to elevated LDH, megakaryocytic colony formation, and JAK2 V617F mutation.
Area of Science:
- Hematology
- Oncology
Background:
- Postpolycythaemic myelofibrosis (PPMF) is a known complication of polycythaemia vera (PV).
- The incidence and predisposing factors for PPMF remain incompletely defined.
Purpose of the Study:
- To determine the incidence of PPMF in a cohort of polycythaemia vera patients.
- To identify predisposing factors associated with the evolution of PV to PPMF.
Main Methods:
- Kaplan-Meier analysis and log-rank test were used to analyze PPMF probability.
- 116 patients with newly diagnosed PV were followed for a mean of 8 years.
Main Results:
- 15% of PV patients evolved to PPMF over the follow-up period.
- The 15-year actuarial probability of PPMF was 34%.
- Predisposing factors for PPMF included endogenous megakaryocytic colony formation, elevated serum lactate dehydrogenase (LDH), and JAK2 V617F heterozygosity.
Conclusions:
- PPMF is a frequent complication of PV, with a significant probability at 15 years.
- Elevated LDH, endogenous megakaryocytic colony formation, and JAK2 V617F mutation are associated with an increased risk of PPMF in PV patients.
Related Concept Videos
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...

